June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
HLA class I expression in cell lines derived from conjunctival melanoma and retinoblastoma using allele-specific monoclonal antibodies and flow cytometry
Author Affiliations & Notes
  • Rind Smesseim
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Jinfeng Cao
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • T Huibertus Van Essen
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Arend Mulder
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Elsbeth van Zeeburg
    The Rotterdam Ophthalmic Institute and the Rotterdam Eye Hospital, Rotterdam, Netherlands
  • Bruce R Ksander
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA
  • Martine J Jager
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Footnotes
    Commercial Relationships Rind Smesseim, None; Jinfeng Cao, None; T Van Essen, None; Arend Mulder, None; Elsbeth van Zeeburg, None; Bruce Ksander, None; Martine Jager, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 68. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rind Smesseim, Jinfeng Cao, T Huibertus Van Essen, Arend Mulder, Elsbeth van Zeeburg, Bruce R Ksander, Martine J Jager; HLA class I expression in cell lines derived from conjunctival melanoma and retinoblastoma using allele-specific monoclonal antibodies and flow cytometry. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):68. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The expression of human leukocyte antigen (HLA) on tumor cells may influence the immunological recognition and response. Malignant cells often change their HLA class I antigens to escape immunosurveillance. To examine whether immunotherapy is possible in conjunctival melanoma and retinoblastoma we investigated the HLA class I surface expression by using allele-specific antibodies in flow cytometry. We furthermore analyzed the effect of interferon gamma (IFN-γ) stimulation on HLA expression.

Methods: Three conjunctival melanoma (CRMM1, CRMM2 and CM2005.1) and three retinoblastoma (Rb116, Rb125 and Rb143) cell lines were HLA gene-typed at the Department for Immunohematology and Blood Transfusion (IHB), The Netherlands. Cells were grown in culture in the presence or absence of recombinant IFN-γ (100 and 200 U/ml) for 48 hours and prepared for flow cytometry. Based on the HLA-typing, HLA allele-specific monoclonal antibodies against class I were selected. Flow cytometry was performed and cellular surface HLA-expression measured. For Western blot analysis, a lysate was made to determine the expression of MHC class I.

Results: We analyzed the HLA allele-specific expression on three conjunctival melanoma and three retinoblastoma cell lines by flow cytometry. In general, a lower expression of antigen specific and allele-specific HLA class I expression was observed in both types of malignancies. In one retinoblastoma cell line (Rb143) no class I expression was observed without IFN-γ stimulation but it was restored after incubation with IFN-γ. Two of the three conjunctival melanoma (CRMM1 and CRMM2) cell lines showed loss of expression of specific HLA class I alleles (respectively HLA-A2 and HLA-B44) which did not recover after IFN-γ stimulation.

Conclusions: We were able to determine HLA expression on three new retinoblastoma cell lines and three conjunctival cell lines, and found a defect in expression of particular HLA specific alleles which were not restored by IFN-γ stimulation. This loss of antigen expression may help ocular tumors to escape the immune response and complicate the development of immunotherapy.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×